Page 47 - 南京医科大学自然版

第46卷第8期 史仲珣，黄 菲，朱华渊，等. 慢性粒单核细胞白血病合并淋巴/浆细胞肿瘤9例临床分析［J］.
2026年8月 南京医科大学学报（自然科学版），2026，46（8）：1145-1153 ·1153 ·

Author’s Contributions： ［9］ SUCH E，GERMING U，MALCOVATI L，et al. Develop⁃
SHEN Wenyi and SHI Zhongxun designed the study，did ment and validation of a prognostic scoring system for
statistical analysis and clinical interpretation. SHI Zhongxun， patients with chronic myelomonocytic leukemia［J］.
HUANG Fei，ZHU Huayuan，HONG Ming，QU Xiaoyan，CHEN Blood，2013，121（15）：3005-3015
Yu，and FAN Lei collected clinical data and samples，and ana⁃ ［10］ARBER D A，ORAZI A，HASSERJIAN R P，et al. Inter⁃
lyzed data. WANG Rong，WANG Yan，and YAN Yining per⁃ national consensus classification of myeloid neoplasms
formed the bone marrow examination and analysis. SHI Zhongxun and acute leukemias：integrating morphologic，clinical，
prepared initial draft. SHEN Wenyi reviewed and edited the final and genomic data［J］. Blood，2022，140（11）：1200-1228
manuscript and was responsible for quality control. ［11］BATALLER A，GENER⁃RICOS G，ALMANZA⁃HUANTE
［参考文献］ E，et al. Therapy⁃related chronic myelomonocytic leukemia
does not have the high⁃risk features of a therapy⁃related
［1］ PATNAIK M M，TEFFERI A. Chronic myelomonocytic
neoplasm［J］. Blood Adv，2024，8（11）：2695-2706
leukemia：2024 update on diagnosis，risk stratification
［12］MCNERNEY M E，GODLEY L A，LE BEAU M M. Therapy⁃
and management［J］. American J Hematol，2024，99（6）：
related myeloid neoplasms：when genetics and environ⁃
1142-1165
ment collide［J］. Nat Rev Cancer，2017，17（9）：513-527
［2］ KHOURY J D，SOLARY E，ABLA O，et al. The 5th edition
［13］MARANDO L，CSIZMAR C M，PATNAIK M M. Chronic
of the World Health Organization classification of haema⁃
myelomonocytic leukemia：molecular pathogenesis and
tolymphoid tumours：myeloid and histiocytic/dendritic
therapeutic innovations［J］. Haematologica，2025，110
neoplasms［J］. Leukemia，2022，36（7）：1703-1719
（1）：22-36
［3］ FERRY J A，HILL B，HSI E D. Mature B，T and NK⁃cell，
［14］LIU M C，ZHOU L Y，LIU Q X，et al. Clonal hematopoie⁃
plasma cell and histiocytic/dendritic cell neoplasms：clas⁃
sis of indeterminate potential（CHIP）and risk of non ⁃
sification according to the World Health Organization and
Hodgkin lymphoma：a community⁃based cohort study［J］.
International Consensus Classification［J］. J Hematol Oncol，
Hema Sphere，2025，9（7）：e70187
2024，17（1）：51
［15］ TAKAHASHI K，PEMMARAJU N，STRATI P，et al. Clini⁃
［4］ ALKHATEEB H B，MOHTY R，GREIPP P，et al. Therapy⁃
cal characteristics and outcomes of therapy⁃related chronic
related myeloid neoplasms following chimeric antigen myelomonocytic leukemia［J］. Blood，2013，122（16）：
receptor T⁃cell therapy for non⁃Hodgkin lymphoma［J］.
2807-2811
Blood Cancer J，2022，12（7）：113 ［16］SUBARI S，PATNAIK M，ALFAKARA D，et al. Patients
［5］ NADIMINTI K，SIDIQI M H，MELEVEEDU K，et al. Cha⁃ with therapy⁃related CMML have shorter Median overall
racteristics and outcomes of therapy ⁃ related myeloid survival than those with de novo CMML：mayo clinic long⁃
neoplasms following autologous stem cell transplantation term follow⁃up experience［J］. Clin Lymphoma Myeloma
for multiple myeloma［J］. Blood Cancer J，2021，11（3）： Leuk，2015，15（9）：546-549

63 ［17］ PATNAIK M M，VALLAPUREDDY R，YALNIZ F F，et
［6］ LIU Y，DERKACH A，LEWIS N，et al. Clonal hemato⁃ al. Therapy related ⁃ chronic myelomonocytic leukemia
poiesis in diffuse large B⁃cell lymphoma：clinical impact （CMML）：molecular，cytogenetic，and clinical distinc⁃
and genetic relatedness to lymphoma and therapy⁃related tions from de novo CMML［J］. American J Hematol，
myeloid neoplasm［J］. Haematologica，2023，108（3）： 2018，93（1）：65-73
917-922 ［18］MARTIN P，CHEN Z M，CHESON B D，et al. Long⁃term
［7］ LI X，HUANG H，WANG F，et al. Decoding the immune outcomes，secondary malignancies and stem cell collec⁃
microenvironment of secondary chronic myelomonocytic tion following bendamustine in patients with previously
leukemia due to DLBCL with CD19 CAR ⁃ T failure by treated non⁃Hodgkin lymphoma［J］. Br J Haematol，2017，
single⁃cell RNA⁃seq［J］. Chin Med J（Engl），2025，138 178（2）：250-256
（15）：1866-1881 ［19］SALEEM K，FRANZ J，KLEM M L，et al. Second primary
［8］ ALSULIMAN T，IKHLEF S，STOCKER N，et al. Coexis⁃ malignancies in patients with haematological cancers
tence of three hematological malignancies in association treated with lenalidomide：a systematic review and meta⁃
with a first time documented mutation：“One train can analysis［J］. Lancet Haematol，2022，9（12）：e906-e918
hide another”，and even more!［J］. Curr Res Transl Med， （收稿：2025-12-27；修回：2026-03-10；录用：2026-03-18）
2023，71（3）：103403 （本文编辑：蒋 莉）